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trials (Reck et al. 2009; Sandler et al. 2006) at two time points from baseline: 12 and 
18 months. PFS percentages were applied to the incidence estimations for metastatic 
NSCLC in Italy. Incidence of nonsquamous metastatic NSCLC was estimated as 37% 
of lung cancer incidence retrieved from GLOBOCAN. Sensitivity analysis was con-
ducted varying the percentage of employment pattern (part time/full time) and the 
labor cost. RESULTS: Bevacizumab-based therapy resulted in mean savings due to 
reduced productivity losses per progression-free patient of c20,089 at 12 months and 
c36,160 at 18 months. Changes in employment patterns, from 60% full time/40% 
part time to 80% full time/20% part time, increased cost savings per patient to 
c22,600 and c40,680 12 and 18 months, respectively. CONCLUSIONS: Bevaci-
zumab-based therapy results in societal cost savings due to improved PFS in metastatic 
NSCLC patients.
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OBJECTIVES: The clinical burden of melanoma patients worsens signiﬁ cantly upon 
metastasis. However, little is known regarding how hospitalization burden changes upon 
metastasis. This study compares the hospitalization burden between metastatic and 
nonmetastatic melanoma patients in a geographically diverse commercially insured US 
population. METHODS: Insurance claims (January 1, 2004–June 30, 2009) from the 
HealthCore Integrated Research Database was used to identify patients aged ≥18 years 
with ≥2 melanoma claims (ICD-9-CM 172.xx, V10.82). Two mutually exclusive cohorts 
were formed: 1) metastatic melanoma (MM) cohort with ≥1 claim for metastasis (ICD-
9-CM 196.x-198.x), and 2) non-MM cohort comprising the remaining patients. The 
ﬁ rst claims for MM and melanoma were the index claims for the respective cohorts. 
Hospitalization burden was compared between the two cohorts based on four outcomes. 
The rate of inpatient visits (per-patient-per-month [PPPM]), and the risk of ﬁ rst hospi-
talization from index claim, were compared using Poisson and Cox-proportional 
hazards regression, respectively. The mean days to ﬁ rst hospitalization and the mean 
length of stay (per-patient-per-month [PPPV] ) were compared using generalized linear 
models. RESULTS: The study included 17,756 (mean age 54.4 years, 49.69% female) 
non-MM patients and 636 (mean age 56.3 years, 41.04% female) MM patients. The 
proportion of patients with ≥1 hospitalization was 2.4 times higher in the MM compared 
to the non-MM cohort (45% vs. 19%, P < 0.01). Compared to the non-MM cohort, 
the MM cohort had: four times higher PPPM inpatient visit rate (0.04 vs. 0.01, P < 
0.001), threefold greater risk of ﬁ rst hospitalization (HR: 3.01; 95% CI: 2.61–3.46), 
and shorter mean days to ﬁ rst hospitalization (35 days vs. 309 days, P < 0.001). The 
mean days of inpatient visit (PPPV) were comparable (3.93 vs. 3.54, P = 0.32). CON-
CLUSIONS: The hospitalization burden in metastatic melanoma patients is signiﬁ cantly 
higher than patients whose melanoma has not progressed to metastasis. Treatments that 
improve progression-free survival may reduce this burden.
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OBJECTIVES: The EPICLIN-Lung study aims to provide information on NSCLC 
clinical management across European countries. As part of this study, information on 
resources associated with the diagnosis of NSCLC from ﬁ rst visit to ﬁ nal diagnosis 
across Europe was collected and described. METHODS: The EPICLIN-Lung study 
(NCT00831909) is a noninterventional prospective cohort study conducted in 
Belgium, France, Germany, Greece, Italy, Portugal, Spain, and Turkey. Patients with 
conﬁ rmed NSCLC attending a participating clinical department for the ﬁ rst time 
between January and March 2009 were included. Information on the approach to 
disease diagnosis was recorded at the ﬁ rst visit. Descriptive analyses were performed. 
RESULTS: A total of 3500 patients were included in the analysis and 2691 (76.9%) 
presented with symptoms at ﬁ rst visit. The mean age (SD) of patients was 64.5 (± 
10.5) years. From ﬁ rst visit to ﬁ nal diagnosis, 3124 (89.3%) patients utilized health-
care resources including radiology (51.5%), general practitioner ofﬁ ce (37.7%), other 
resources (19.3%), oncology (19.0%), surgery (17.9%), emergency room (12.8%), 
drug administration facilities (1.6%), and blood-speciﬁ c resources (0.3%). The appli-
cation of tests for diagnosis occurred in 96.0% of patients and included laboratory 
tests (77.5%), bronchoscopy (73.9%), ﬁ ne needle aspiration biopsy (26.5%), other 
tests (20.5%), and biomarker determination (11.3%). Imaging technology was also 
used in disease assessment with scanning the most frequently used technology (88.7% 
of patients), followed by x-ray (65.9%), MRI/CT brain scan (39.5%), PET imaging 
(34.1%), and other imaging tests (21.5%). CONCLUSIONS: The resource used from 
ﬁ rst visit to ﬁ nal diagnosis of NSCLC is not uniform within the patient demographic 
across Europe. In particular, biomarker determination was low but bronchoscopy and 
laboratory tests were relatively high as was the use of imaging technology. a more 
uniform approach in the use of these resources may improve the impact of current 
treatments. More speciﬁ c results will be presented at the meeting.
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OBJECTIVES: We conducted this study to document the health-care resource utiliza-
tion associated with treatment of patients with advanced melanoma. METHODS: 
MELODY (Melanoma treatment patterns and outcomes among patients with unre-
sectable stage III or stage IV disease: a retrospective longitudinal survey) is an obser-
vational study managed at 31 centers in France, Italy, and the UK. Eligible patients 
had attended at one of the sites with a diagnosis of unresectable stage III or IV mela-
noma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis 
(no limit date) until 2008. The primary objective was to document the ﬁ rst-line treat-
ments received by patients. Secondary objectives included ascertaining health-care 
resource utilization related to up to three lines of treatment (anticancer and supportive 
care). Data were collected from patients (n = 776) using a case-report form that 
included information on hospitalizations, outpatient visits, hospice care, and adverse-
event management (transfusions and concomitant medications including antiemetics 
and growth factors). Resource use data were collected from patients (n = 606) that 
received systemic treatment outside a clinical trial and/or supportive care. RESULTS: 
Twenty-nine percent (176/606) of patients required medical management for treat-
ment-related adverse events and 32% (195/606) were hospitalized while receiving 
systemic treatment and/or supportive care with 25% of these having at least four 
hospitalizations. The median duration of hospitalization was 17 days, with 25% 
spending at least 29 days in hospital (may comprise multiple stays). The hospitaliza-
tion rate was higher in patients receiving supportive care than those receiving antican-
cer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalization 
was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive 
care will be presented. CONCLUSIONS: These results from MELODY suggest that 
the systemic and palliative treatments used to manage advanced melanoma are associ-
ated with considerable resource utilization, highlighting the need for more effective 
treatment options.
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OBJECTIVES: To examine the patient characteristics, cancer therapy use, and costs 
among patients with mPC. METHODS: Subjects in the Marketscan Commerical 
Claims and Encounters and Supplemental Medicare databases (July 1, 2004–June 30, 
2008) were included if they received a diagnosis of metastastasis (ICD-9 codes: 
197.x—199.x) on or after the ﬁ rst occurrence of PC (ICD-9 code: 157.x), had no 
claims for other secondary metastases within 6 months of the initial mPC claim (e.g. 
index date), and had continuous insurance coverage from 6 months prior through at 
least 1 month post index. Outpatient cancer therapies and costs are described from 
mPC index until loss to follow-up or end of the data collection period. RESULTS: 
There were 4938 subjects with incident mPC included in the analysis. The mean age 
at index date was 64.8 years (SD = 11.8) and 53.8% were male. Subjects were followed 
an average of 8.3 months post index. Among patients with incident mPC, 53.3% 
received outpatient chemotherapy with gemcitabine (76.4%) being the most com-
monly received therapy. 20.1% of mPC subjects received the targeted agent, erlotinib, 
post-index, with 63.6% of its use occurring in combination with gemcitabine. Subjects 
who received gemcitabine, received an average of 9.5 doses (SD: 8.8) over 108.9 days 
(SD: 129.5). Subjects who received erlotinib, ﬁ lled an average of 3.9 prescriptions (SD: 
4.1) following mPC index. Post-metastases, 84.1% and 73.3% of subjects were hos-
pitalized or visited the ER respectively. The mean cost per month of treating mPC 
subjects was $16,192 (SD = $21,639), with the majority of these costs attributed to 
inpatient stays (57.8%) and outpatient visits (35.0%). Outpatient cancer therapies 
contributed 5.3% of the mean monthly cost post index. CONCLUSIONS: Gem-
citabine was the predominant cancer therapy among subjects with incident mPC. 
Outpatient cancer drugs constituted a small portion of the total mean monthly cost 
of mPC.
